Regeneron Pharmaceuticals, Inc. (REGN)
| Market Cap | 96.81B |
| Revenue (ttm) | 13.12B |
| Net Income (ttm) | 3.95B |
| Shares Out | 107.94M |
| EPS (ttm) | 34.77 |
| PE Ratio | 25.79 |
| Forward PE | 19.56 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 501,396 |
| Open | 913.97 |
| Previous Close | 893.99 |
| Day's Range | 891.38 - 923.58 |
| 52-Week Range | 684.81 - 998.33 |
| Beta | 0.14 |
| Analysts | Buy |
| Price Target | 973.17 (+8.51%) |
| Earnings Date | May 2, 2024 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2023, REGN's revenue was $13.12 billion, an increase of 7.76% compared to the previous year's $12.17 billion. Earnings were $3.95 billion, a decrease of -8.87%.
Financial StatementsAnalyst Forecast
According to 24 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is $973.17, which is an increase of 8.51% from the latest price.
News
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharma...
The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) on behalf of investors concer...
Regeneron to defend US Justice Department's complaint on drug-pricing manipulation
Regeneron Pharmaceuticals said on Monday the U.S. Justice Department's complaint against the company misreporting the average sales price for its macular degeneration drug Eylea is "meritless" and it ...
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharma...
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharma...
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharma...
Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to Watch
Shares in biotech giant Regeneron Pharmaceuticals (REGN) go under the microscope Thursday after the U.S. Department of Justice (DOJ) accused the company of manipulating Medicare's drug pricing reporti...
US Justice department files complaint against Regeneron, alleges fraudulent drug pricing
The U.S. Justice Department said on Wednesday it had filed a false claims act complaint against Regeneron Pharmaceuticals , claiming the company filed false average sales price reports.
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Regulatory applications for linvoseltamab currently ...
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
TARRYTOWN, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2024 financial and operating results on Thursda...
US FDA declines to approve Regeneron's blood cancer therapy
Regeneron Pharmaceuticals said on Monday the U.S. FDA has declined to approve its blood cancer therapy for two most common subtypes of non-Hodgkin lymphoma due to an issue related to enrollment of its...
Regeneron Provides Update on Biologics License Application for Odronextamab
TARRYTOWN, N.Y., March 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued Complete Response Letters...
US appeals court revives Regeneron's antitrust lawsuit against Novartis
A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders inclu...
Calls of the Day: Regeneron, Thermo Fisher, Darden Restaurants and Nucor
The Investment Committee debate the latest calls of the day on a number of stocks.
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
$250,000 top award goes to Achyuta Rajaram in the nation's oldest and most prestigious Science, Technology, Engineering and Math (STEM) competition for high school seniors TARRYTOWN, N.Y. and WASHING...
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH) Approval extends treatment of Praluent to children aged 8 and older with hete...
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
Published results show EYLEA HD with extended 12- or 16-week dosing regimens demonstrated non-inferior vision gains to standard of care EYLEA ® (aflibercept) Injection 2 mg with fixed 8-week dosing in...
GENESIS Pharma Announces an Exclusive Distribution Agreement With Regeneron Pharmaceuticals to Commercialize cemiplimab in Greece, Cyprus and Malta
ATHENS, Greece--(BUSINESS WIRE)--GENESIS Pharma announces an exclusive distribution agreement with Regeneron Pharmaceuticals to commercialize cemiplimab in Greece, Cyprus and Malta.
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
Priority Review granted based on positive results from two Phase 3 trials; i f approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for this disease in m...
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Dupixent ® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
TARRYTOWN, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the ...
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
Japan first in the world to approve Dupixent ® for chronic spontaneous urticaria (CSU) Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to pl...
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for Dup...
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
Regeneron beats quarterly revenue estimates
Drug maker Regeneron beat fourth-quarter revenue estimates on Friday.